EA033947B1 - Набор полипептидов для идентификации и/или элиминации клеток, его применение, молекула нуклеиновой кислоты, которая кодирует один из полипептидов набора, набор нуклеиновых кислот, который кодирует набор полипептидов, фармацевтическая композиция, содержащая эти наборы - Google Patents

Набор полипептидов для идентификации и/или элиминации клеток, его применение, молекула нуклеиновой кислоты, которая кодирует один из полипептидов набора, набор нуклеиновых кислот, который кодирует набор полипептидов, фармацевтическая композиция, содержащая эти наборы Download PDF

Info

Publication number
EA033947B1
EA033947B1 EA201400811A EA201400811A EA033947B1 EA 033947 B1 EA033947 B1 EA 033947B1 EA 201400811 A EA201400811 A EA 201400811A EA 201400811 A EA201400811 A EA 201400811A EA 033947 B1 EA033947 B1 EA 033947B1
Authority
EA
Eurasian Patent Office
Prior art keywords
cells
domain
antigen
cell
hla
Prior art date
Application number
EA201400811A
Other languages
English (en)
Russian (ru)
Other versions
EA201400811A1 (ru
Inventor
Гернот Штулер
Original Assignee
Юлиус-Максимилианс-Универзитет Вюрцбург
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47715984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA033947(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Юлиус-Максимилианс-Универзитет Вюрцбург filed Critical Юлиус-Максимилианс-Универзитет Вюрцбург
Publication of EA201400811A1 publication Critical patent/EA201400811A1/ru
Publication of EA033947B1 publication Critical patent/EA033947B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
EA201400811A 2012-01-13 2013-01-14 Набор полипептидов для идентификации и/или элиминации клеток, его применение, молекула нуклеиновой кислоты, которая кодирует один из полипептидов набора, набор нуклеиновых кислот, который кодирует набор полипептидов, фармацевтическая композиция, содержащая эти наборы EA033947B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12151125 2012-01-13
PCT/EP2013/050603 WO2013104804A2 (en) 2012-01-13 2013-01-14 Dual antigen-induced bipartite functional complementation

Publications (2)

Publication Number Publication Date
EA201400811A1 EA201400811A1 (ru) 2014-12-30
EA033947B1 true EA033947B1 (ru) 2019-12-12

Family

ID=47715984

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400811A EA033947B1 (ru) 2012-01-13 2013-01-14 Набор полипептидов для идентификации и/или элиминации клеток, его применение, молекула нуклеиновой кислоты, которая кодирует один из полипептидов набора, набор нуклеиновых кислот, который кодирует набор полипептидов, фармацевтическая композиция, содержащая эти наборы

Country Status (24)

Country Link
US (3) US20150079093A1 (https=)
EP (3) EP2802607B1 (https=)
JP (1) JP6408915B2 (https=)
KR (2) KR20200040893A (https=)
CN (2) CN108034006A (https=)
AU (1) AU2013208895B2 (https=)
CA (1) CA2861003C (https=)
CY (1) CY1119928T1 (https=)
DK (1) DK2802607T3 (https=)
EA (1) EA033947B1 (https=)
ES (1) ES2653287T3 (https=)
HR (1) HRP20171912T1 (https=)
HU (1) HUE035207T2 (https=)
IL (1) IL233566B (https=)
LT (1) LT2802607T (https=)
MX (1) MX359411B (https=)
NO (1) NO2802607T3 (https=)
PL (1) PL2802607T3 (https=)
PT (1) PT2802607T (https=)
RS (1) RS56773B1 (https=)
SG (1) SG11201403997SA (https=)
SI (1) SI2802607T1 (https=)
WO (1) WO2013104804A2 (https=)
ZA (1) ZA201405658B (https=)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA118950C2 (uk) 2011-04-22 2019-04-10 Аптево Рісьорч Енд Девелопмент Ллс Поліпептид, який зв'язує специфічний мембранний антиген простати та комплекс т-клітинного рецептора
US11096994B2 (en) 2012-10-30 2021-08-24 Aravax Pty Ltd Immunotherapeutic molecules and uses thereof
CN121714673A (zh) 2013-09-25 2026-03-24 阿拉沃克斯有限公司 新型免疫治疗组合物及其用途
AU2015236054B2 (en) * 2014-03-25 2019-11-21 Five3 Genomics, Llc Systems and methods for RNA analysis in functional confirmation of cancer mutations
EP2985294A1 (en) 2014-08-14 2016-02-17 Deutsches Krebsforschungszentrum Recombinant antibody molecule and its use for target cell restricted T cell activation
CA2970924A1 (en) * 2014-10-31 2016-05-06 H. Lee Moffitt Cancer Center And Research Institute, Inc. Tetravalent tlr9 bispecific antibody
CN104592391B (zh) * 2015-01-21 2020-08-21 武汉友芝友生物制药有限公司 一种双特异性抗体EpCAM×CD3的构建及应用
IL294055A (en) * 2015-03-20 2022-08-01 Childrens Nat Medical Ct Generating virus or other antigen-specific t cells from a naive t cell population
EA201792573A1 (ru) 2015-05-21 2018-04-30 Харпун Терапьютикс, Инк. Триспецифические связанные белки и способы их применения
TWI731861B (zh) 2015-06-16 2021-07-01 美商建南德克公司 FcRH5之人源化及親和力成熟抗體及使用方法
EP3112375A1 (en) * 2015-07-03 2017-01-04 Ludwig-Maximilians-Universität München Antigenic peptides for the diagnosis, therapy monitoring and/or treatment of psoriasis vulgaris
EP3352760B1 (en) 2015-09-21 2026-03-11 Aptevo Research and Development LLC Cd3 binding polypeptides
US10339274B2 (en) * 2015-10-12 2019-07-02 Nantomics, Llc Viral neoepitopes and uses thereof
ES2873846T5 (en) 2015-11-19 2025-06-23 Revitope Ltd Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells
CN106810610A (zh) * 2015-11-30 2017-06-09 中国科学院深圳先进技术研究院 抗EpCAM和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
RU2767329C2 (ru) * 2016-02-06 2022-03-17 Эпимаб Биотерапьютикс, Инк. Иммуноглобулин с тандемными fab-фрагментами и варианты его применения
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
WO2017189751A1 (en) 2016-04-26 2017-11-02 The University Of Utah Research Foundation Target-binding activated split reporter systems for analyte detection and related components and methods
CN116987189A (zh) 2016-05-20 2023-11-03 哈普恩治疗公司 单链可变片段cd3结合蛋白质
JP7101621B2 (ja) 2016-05-20 2022-07-15 ハープーン セラピューティクス，インク． 単一ドメイン血清アルブミン結合タンパク質
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
CN105920618A (zh) * 2016-06-13 2016-09-07 上海交通大学医学院附属新华医院 一种生物靶向纳米基因材料及其制造方法
EP3263595A1 (en) 2016-06-30 2018-01-03 Medizinische Hochschule Hannover Fusion protein for use in the treatment of hvg disease
EP3714944A1 (en) * 2019-03-29 2020-09-30 Medizinische Hochschule Hannover Car for use in the treatment of hvg disease
CN108085333B (zh) * 2016-11-14 2021-06-29 中国科学院分子植物科学卓越创新中心 一种延缓薯类植物生理性变质的方法
EP3544629A4 (en) 2016-11-23 2020-06-17 Harpoon Therapeutics, Inc. PSMA TO BE TRISPECIFIC PROTEINS AND METHOD FOR USE THEREOF
CN110198955A (zh) 2016-11-23 2019-09-03 哈普恩治疗公司 前列腺特异性膜抗原结合蛋白质
WO2018136725A1 (en) * 2017-01-19 2018-07-26 Harpoon Therapeutics, Inc. Innate immune cell inducible binding proteins and methods of use
JP7556687B2 (ja) 2017-02-24 2024-09-26 中外製薬株式会社 薬学的組成物、抗原結合分子、治療方法、およびスクリーニング方法
EP3589662A4 (en) 2017-02-28 2020-12-30 Harpoon Therapeutics, Inc. INDUCTIBLE MONOVALENT ANTIGEN BINDING PROTEIN
JP7618192B2 (ja) * 2017-03-28 2025-01-21 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 移植された組織を拒絶反応から保護するための方法
WO2018209304A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
AU2018265856B2 (en) 2017-05-12 2023-04-27 Harpoon Therapeutics, Inc. Mesothelin binding proteins
IL302613B2 (en) 2017-09-08 2025-04-01 Maverick Therapeutics Inc Binding proteins are activated under limited conditions
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
HRP20241268T1 (hr) 2017-10-13 2024-12-06 Harpoon Therapeutics, Inc. Trispecifični proteini i postupci primjene
GB201719646D0 (en) * 2017-11-27 2018-01-10 Bivictrix Therapeutics Ltd Therapy
WO2019122350A1 (en) 2017-12-21 2019-06-27 Gernot Stuhler Specific dosage regimen for hemibody therapy
MX2020011588A (es) 2018-05-03 2020-12-07 Shanghai Epimab Biotherapeutics Co Ltd Anticuerpos de alta afinidad a pd-1 y lag-3 y proteinas de union bispecificas preparadas a partir de las mismas.
KR20210020903A (ko) 2018-05-14 2021-02-24 하푼 테라퓨틱스, 인크. 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티
CA3100349A1 (en) * 2018-05-17 2019-11-21 The Board Of Trustees Of The Leland Stanford Junior University Receptor inhibition by phosphatase recruitment
CN112673021A (zh) * 2018-07-02 2021-04-16 综合医院公司 抗体肿瘤靶向组装复合物
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
SG11202103022WA (en) 2018-09-25 2021-04-29 Harpoon Therapeutics Inc Dll3 binding proteins and methods of use
CA3120800A1 (en) * 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
WO2020181140A1 (en) 2019-03-05 2020-09-10 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins
EP3962950A1 (en) 2019-05-02 2022-03-09 The General Hospital Corporation Teac and attac immunooncology compositions and methods
US12516128B2 (en) 2019-05-14 2026-01-06 Harpoon Therapeutics, Inc. EpCAM binding proteins and methods of use
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
AR119382A1 (es) * 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
WO2021041300A2 (en) * 2019-08-23 2021-03-04 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
BR112022014568A2 (pt) * 2020-01-23 2022-09-27 Exuma Biotech Corp Receptores de antígeno quiméricos contra her2 e métodos de uso dos mesmos
CN116407626A (zh) * 2020-01-29 2023-07-11 美勒斯公司 用于调节免疫细胞衔接效应的手段和方法
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
JP2023533533A (ja) * 2020-07-10 2023-08-03 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がん細胞に結合し、当該細胞に対して放射性ヌクレオチドを標的化する抗体
US20230357398A1 (en) 2020-09-24 2023-11-09 Morphosys Ag Novel human antibodies binding to human cd3 epsilon
WO2022140388A1 (en) 2020-12-21 2022-06-30 Allogene Therapeutics, Inc. Protease-activating cd45-gate car
EP4277705A1 (en) * 2021-01-12 2023-11-22 F. Hoffmann-La Roche AG Split antibodies which bind to cancer cells and target radionuclides to said cells
CN112724236B (zh) * 2021-01-15 2022-03-04 武汉大学 一种两性蛋白1的抗原肽及其抗体与应用
US12291575B2 (en) 2021-05-14 2025-05-06 Genentech, Inc. Methods for treatment of CD20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
US20240294673A1 (en) * 2021-05-28 2024-09-05 Julius-Maximilians-Universitaet Wuerzburg Recombinant proteinaceous binding molecules
CA3227537A1 (en) 2021-07-27 2023-02-02 Morphosys Ag Combinations of antigen binding molecules
CN113846115B (zh) * 2021-09-24 2023-10-17 广州医科大学 一种屋尘螨I类变应原pro-Der p 1重组蛋白及其制备方法与应用
WO2023183927A2 (en) * 2022-03-24 2023-09-28 Actinium Pharmaceuticals, Inc. Humanized anti-cd45 antibodies
CN114773452A (zh) * 2022-04-21 2022-07-22 谭宏凯 牛乳乳清主要过敏原α-乳白蛋白的IgE结合表位
US20230382960A1 (en) * 2022-05-27 2023-11-30 Arizona Board Of Regents On Behalf Of Arizona State University Truncated chlorotoxin fusion proteins and methods of use thereof
WO2024026317A2 (en) * 2022-07-25 2024-02-01 Vironexis Biotherapeutics Inc. Adeno-associated virus vectors and methods of their use for reducing the risk of, treating, and preventing metastasis
CN117305248A (zh) * 2022-09-09 2023-12-29 复星凯特生物科技有限公司 抗EGFR和cMet双特异性嵌合抗原受体及其应用
EP4619427A1 (en) 2022-11-15 2025-09-24 F. Hoffmann-La Roche AG Recombinant binding proteins with activatable effector domain
JP2025539760A (ja) 2022-11-15 2025-12-09 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗原結合分子
EP4378529A1 (en) * 2022-12-03 2024-06-05 Universitätsklinikum Hamburg-Eppendorf Antibody for use in a therapy involving effector cell engagement
WO2024208777A1 (en) * 2023-04-03 2024-10-10 F. Hoffmann-La Roche Ag All-in-one agonistic antibodies
CN120917044A (zh) * 2023-04-03 2025-11-07 豪夫迈·罗氏有限公司 激动性拆分型抗体
WO2024241205A1 (en) * 2023-05-19 2024-11-28 Seoul National University R&Db Foundation Safety control of switchable chimeric antigen receptor t cells using dose-adjustable adaptors
WO2025003511A1 (en) 2023-06-30 2025-01-02 Morphosys Ag Dual-targeting of flt3 and cd123 co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025016902A1 (en) * 2023-07-14 2025-01-23 Julius-Maximilians-Universität Würzburg Multivalent single-partite antibodies for dual-antigen restricted immunotherapy
CN121712801A (zh) 2023-08-14 2026-03-20 莫佛塞斯有限责任公司 包含空间位阻部分的CyCAT半体分子
WO2025082777A1 (en) 2023-10-17 2025-04-24 Morphosys Ag Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules
WO2025237931A1 (en) * 2024-05-15 2025-11-20 F. Hoffmann-La Roche Ag Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015210A1 (en) * 1992-01-23 1993-08-05 Merck Patent Gmbh Monomeric and dimeric antibody-fragment fusion proteins
WO2004042404A1 (en) * 2002-11-07 2004-05-21 Erasmus Universiteit Rotterdam Fret probes and methods for detecting interacting molecules
EP1561759A1 (en) * 2002-10-11 2005-08-10 Chugai Seiyaku Kabushiki Kaisha Cell death-inducing agent
WO2007062466A1 (en) * 2005-11-29 2007-06-07 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
EP2133093A1 (en) * 2007-03-12 2009-12-16 Chugai Seiyaku Kabushiki Kaisha Remedy for chemotherapy-resistant cancer containing hla class i-recognizing antibody as the active ingredient and use of the same
WO2010022225A1 (en) * 2008-08-20 2010-02-25 Ibc Pharmaceuticals, Inc. Dock-and-lock (dnl) vaccines for cancer therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB9221657D0 (en) * 1992-10-15 1992-11-25 Scotgen Ltd Recombinant bispecific antibodies
US7435797B2 (en) * 2002-04-10 2008-10-14 Genentech, Inc. Anti-HER2 antibody variants
US20060252028A1 (en) 2002-08-16 2006-11-09 Hiroshi Ueda Method of assaying interaction between proteins
DE602004030811D1 (de) 2003-10-16 2011-02-10 Micromet Ag Multispezifische deimmunisierte cd3-bindende moleküle
GB0421836D0 (en) * 2004-10-01 2004-11-03 Avidex Ltd T cell receptors containing a non-native disulfide interchain bond linked to immunomodulatory agents
GB0919751D0 (en) * 2009-11-11 2009-12-30 King S College Hospital Nhs Fo Conjugate molecule
DK2560993T3 (da) * 2010-04-20 2024-10-14 Genmab As Heterodimeric antibody fc-containing proteins and methods for production thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993015210A1 (en) * 1992-01-23 1993-08-05 Merck Patent Gmbh Monomeric and dimeric antibody-fragment fusion proteins
EP1561759A1 (en) * 2002-10-11 2005-08-10 Chugai Seiyaku Kabushiki Kaisha Cell death-inducing agent
WO2004042404A1 (en) * 2002-11-07 2004-05-21 Erasmus Universiteit Rotterdam Fret probes and methods for detecting interacting molecules
WO2007062466A1 (en) * 2005-11-29 2007-06-07 The University Of Sydney Demibodies: dimerisation-activated therapeutic agents
EP2133093A1 (en) * 2007-03-12 2009-12-16 Chugai Seiyaku Kabushiki Kaisha Remedy for chemotherapy-resistant cancer containing hla class i-recognizing antibody as the active ingredient and use of the same
WO2010022225A1 (en) * 2008-08-20 2010-02-25 Ibc Pharmaceuticals, Inc. Dock-and-lock (dnl) vaccines for cancer therapy

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BIOLINK PARTNERS LTD: "Demibodies: Dimerization-activated therapeutic antibodies", INTERNET CITATION, 2007, XP003013805, Retrieved from the Internet: URL:http://www.biolink.org.au/library/File/Demibodies.pdf [retrieved on 2007-01-01], the whole document *
HEUSER C, ET AL.: "An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, vol. 89, no. 6, 1 January 2003 (2003-01-01), GB, pages 1130 - 1139, XP003013806, ISSN: 0007-0920, DOI: 10.1038/sj.bjc.6601267 *
KAWASHIMA R, ABEI M, FUKUDA K, NAKAMURA K, MURATA T, WAKAYAMA M, SEO E, HASEGAWA N, MIZUGUCHI H, OBATA Y, HYODO I, HAMADA H, YOKOY: "EpCAM- and EGFR-targeted selective gene therapy for biliary cancers using Z33-fiber-modified adenovirus.", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC., US, vol. 129, no. 5, 1 September 2011 (2011-09-01), US, pages 1244 - 1253, XP002699347, ISSN: 0020-7136, DOI: 10.1002/ijc.25758 *
KIMURA, N. KAWAI, S. KINOSHITA, Y. ISHIGURO, T. AZUMA, Y. OZAKI, S. ABE, M. SUGIMOTO, M. HIRATA, Y. ORITA, T. : "2D7 diabody bound to the @a2 domain of HLA class I efficiently induces caspase-independent cell death against malignant and activated lymphoid cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 325, no. 4, 24 December 2004 (2004-12-24), AMSTERDAM, NL, pages 1201 - 1209, XP004649732, ISSN: 0006-291X, DOI: 10.1016/j.bbrc.2004.10.163 *
KIPRIYANOV S M, GALL LE F: "Generation and production of engineered antibodies.", MOLECULAR BIOTECHNOLOGY, HUMANA PRESS, BOSTON, vol. 26, no. 1, 1 January 2004 (2004-01-01), Boston, pages 39 - 60, XP009044299, ISSN: 1073-6085, DOI: 10.1385/MB:26:1:39 *
MILLER K, MENG G, LIU J, HURST A, HSEI V, WONG W L, EKERT R, LAWRENCE D, SHERWOOD S, DEFORGE L, GAUDREAULT J, KELLER G, SLIWKOWSKI: "Design, construction, and in vitro analyses of multivalent antibodies.", THE JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 170, no. 9, 1 May 2003 (2003-05-01), US, pages 4854 - 4861, XP002675910, ISSN: 0022-1767, DOI: 10.4049/jimmunol.170.9.4854 *
OHIRO YOSHIYUKI, ET AL: "A homogeneous and noncompetitive immunoassay based on the enhanced fluorescence resonance energy transfer by leucine zipper interaction.", ANALYTICAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 74, no. 22, 15 November 2002 (2002-11-15), US, pages 5786 - 5792, XP002605915, ISSN: 0003-2700, DOI: 10.1021/AC0203387 *
OLIVER SEIFERT, ALINE PLAPPERT, NADINE HEIDEL, SINA FELLERMEIER, SYLVIA K.E. MESSERSCHMIDT, FABIAN RICHTER AND ROLAND E. KONTERMAN: "The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity.", PROTEIN ENGINEERING, DESIGN AND SELECTION, OXFORD JOURNAL, LONDON, GB, vol. 25, no. 10, 1 October 2012 (2012-10-01), GB, pages 603 - 612, XP002699346, ISSN: 1741-0126, DOI: 10.1093/protein/gzs059 *
RHEINNECKER M, HARDT C, ILAG L L, KUFER P, GRUBER R, HOESS A, LUPAS A, ROTTENBERGER C, PL�CKTHUN A, PACK P: "Multivalent antibody fragments with high functional affinity for a tumor-associated carbohydrate antigen.", THE JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 157, no. 7, 1 October 1996 (1996-10-01), US, pages 2989 - 2997, XP002675911, ISSN: 0022-1767 *
VAN BEUSECHEM V W, GRILL J, MASTENBROEK D C, WICKHAM T J, ROELVINK P W, HAISMA H J, LAMFERS M L, DIRVEN C M, PINEDO H M, GERRITSEN: "Efficient and selective gene transfer into primary human brain tumors by using single-chain antibody-targeted adenoviral vectors with native tropism abolished.", JOURNAL OF VIROLOGY., THE AMERICAN SOCIETY FOR MICROBIOLOGY., US, vol. 76, no. 6, 1 March 2002 (2002-03-01), US, pages 2753 - 2762, XP002699348, ISSN: 0022-538X, DOI: 10.1128/JVI.76.6.2753-2762.2002 *
XIE, Z. GUO, N. YU, M. HU, M. SHEN, B.: "A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis", JOURNAL OF IMMUNOLOGICAL METHODS., ELSEVIER SCIENCE PUBLISHERS B.V.,AMSTERDAM., NL, vol. 296, no. 1-2, 1 January 2005 (2005-01-01), NL, pages 95 - 101, XP004738464, ISSN: 0022-1759, DOI: 10.1016/j.jim.2004.11.005 *
ZHAO, Y. RUSS, M. MORGAN, C. MULLER, S. KOHLER, H.: "Therapeutic applications of superantibodies", DRUG DISCOVERY TODAY, ELSEVIER, AMSTERDAM, NL, vol. 10, no. 18, 15 September 2005 (2005-09-15), AMSTERDAM, NL, pages 1231 - 1236, XP005103828, ISSN: 1359-6446, DOI: 10.1016/S1359-6446(05)03530-0 *

Also Published As

Publication number Publication date
AU2013208895B2 (en) 2017-07-06
CN104159923A (zh) 2014-11-19
RS56773B1 (sr) 2018-04-30
JP2015505319A (ja) 2015-02-19
SI2802607T1 (en) 2018-01-31
WO2013104804A2 (en) 2013-07-18
US20210188997A9 (en) 2021-06-24
US20190284296A1 (en) 2019-09-19
SG11201403997SA (en) 2014-08-28
HRP20171912T1 (hr) 2018-02-09
MX359411B (es) 2018-09-27
US20220340681A1 (en) 2022-10-27
KR102100817B1 (ko) 2020-04-17
LT2802607T (lt) 2018-02-12
MX2014008468A (es) 2015-02-05
IL233566A0 (en) 2014-08-31
KR20140130679A (ko) 2014-11-11
US20150079093A1 (en) 2015-03-19
CN104159923B (zh) 2018-01-23
BR112014017182A2 (pt) 2020-10-27
EP3333190A1 (en) 2018-06-13
DK2802607T3 (en) 2018-01-08
ZA201405658B (en) 2016-05-25
AU2013208895A1 (en) 2014-08-28
NO2802607T3 (https=) 2018-03-03
KR20200040893A (ko) 2020-04-20
CA2861003A1 (en) 2013-07-18
EP2802607A2 (en) 2014-11-19
US11427644B2 (en) 2022-08-30
CY1119928T1 (el) 2018-12-12
ES2653287T3 (es) 2018-02-06
EA201400811A1 (ru) 2014-12-30
EP2802607B1 (en) 2017-10-04
EP3907241A1 (en) 2021-11-10
CA2861003C (en) 2023-03-28
JP6408915B2 (ja) 2018-10-17
IL233566B (en) 2018-07-31
HUE035207T2 (en) 2018-05-02
CN108034006A (zh) 2018-05-15
WO2013104804A3 (en) 2013-11-21
HK1200175A1 (en) 2015-07-31
PL2802607T3 (pl) 2018-03-30
PT2802607T (pt) 2018-01-03

Similar Documents

Publication Publication Date Title
US20220340681A1 (en) Dual antigen-induced bipartite functional complementation
Zhao et al. Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential
KR102091297B1 (ko) 항원-형질감염된 t 세포와 함께 사용되는 이중특이적 항체 분자 및 의약에서의 이들의 용도
Schiller et al. CD19-specific triplebody SPM-1 engages NK and γδ T cells for rapid and efficient lysis of malignant B-lymphoid cells
AU2026202432A1 (en) Antibody tumor-targeting assembly complexes
US11046764B2 (en) Native human antibodies for immune checkpoint modulation targets TIM-3 and B7-H3
JP2021528382A (ja) 免疫エフェクター細胞を腫瘍細胞へ誘引する方法及び手段
CN112442126A (zh) 一种抗人cs1抗原的单克隆抗体及其car-t细胞
HK1200175B (en) Dual antigen-induced bipartite functional complementation
BR112014017182B1 (pt) Conjunto de polipeptídeos, molécula de ácido nucleico ou um conjunto de moléculas de ácidos nucleicos, composição farmacêutica e kit
WO2024012585A1 (zh) Nkg2d嵌合抗原受体和pd1抑制剂联合治疗癌症的方法和药物
Banaszek Dual Antigen-Restricted Complementation of a Two-Part Trispecific Antibody for Targeted Immunotherapy of Blood Cancer
JP6952295B2 (ja) ヒト抗ｈｌａモノクローナル抗体の作製方法
WO2024133584A2 (en) Antigen binding proteins
丸田雅樹 Direct comparison of targetreactivity and cross-reactivity induced by CAR-and BiTEredirected T cells for the development of antibody-based T-cell therapy

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM